With 36.44 million shares changed hands, the volume of the stock remained heavier than its average volume of 26890.0 shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $16.25 whereas the lowest price it dropped to was $8.92. The 52-week range on RADX shows that it touched its highest point at $11.00 and its lowest point at $3.50 during that stretch. It currently has a 1-year price target of $15.58. Beta for the stock currently stands at 1.56.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of RADX was up-trending over the past week, with a rise of 142.03%, but this was up by 134.14% over a month. Three-month performance surged to 70.08% while six-month performance rose 127.14%. The stock gained 136.75% in the past year, while it has lost -39.84% so far this year. A look at the trailing 12-month EPS for RADX yields -3.47 with Next year EPS estimates of -3.13. For the next quarter, that number is -1.95. This implies an EPS growth rate of 4.47% for this year and 5.42% for next year. EPS is expected to grow by 20.65% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of -71.92%.
Float and Shares Shorts:
On 2025-11-28, short shares totaled 33462.0, which was 42.0 higher than short shares on 1761868800. In addition to Mr. Paul Edward-Alexander Hopper A.S.i.A, B.A (UNSW), FAICD as the firm’s Founder & Executive Chairman, Mr. Riccardo Canevari serves as its MD, CEO & Director.
Analysts Ratings:
In the same way, a target price assigned to a stock can also reveal much about its potential. With RADX analysts setting a high price target of 30.384361 and a low target of 12.184679, the average target price over the next 12 months is 16.274117. Based on these targets, RADX could surge 185.84% to reach the target high and rise by 14.63% to reach the target low. Reaching the average price target will result in a growth of 53.1% from current levels.
